Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice

American Heart Journal

Volumn 157, Issue 5, 2009, Pages 883-888

  Goy, Jean Jacques ^a   Urban, Philip ^b   Kaufmann, Urs ^c   Seydoux, Charles ^a   De Benedetti, Edoardo ^b   Berger, Alexandre ^a  

^a Clinique Cecil   (Switzerland)

^b LA TOUR HOSPITAL   (Switzerland)

^c Abteilung fur Kardiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HOSPITAL; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROSPECTIVE STUDIES; RISK FACTORS; SWITZERLAND; TIME FACTORS;

EID: 64449085916     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.02.007     Document Type: Article

References (32)

1. Sigwart U., Puel J., Mirkovitch V., et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316 (1987) 701-716
2. Morice M.C., Serruys P.W., Sousa J.E., et al., RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
4. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455
5. Urban P., Gershlick A.H., Guagliumi G., et al. e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
6. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
7. Schampaert E., Moses J.W., Schofer J., et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 98 (2006) 36-41
8. Morice M.C., Serruys P.W., Barragan P., et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 50 (2007) 1299-1304
9. Weisz G., Leon M.B., Holmes Jr. D.R., et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 47 (2006) 1350-1355
10. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
11. Lagerqvist B., James S.K., Stenestrand U., et al. Long term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
12. Daemen J., Kukreja N., van Twisk P.H., et al. Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry. Am J Cardiol 101 (2008) 1105-1111
13. Anstrom K.J., Kong D.F., Shaw L.K., et al. Long-term clinical outcomes following coronary stenting. Arch Intern Med 168 (2008) 1647-1655
14. Kelbaek H., Kløvgaard L., Helqvist S., et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J Am Coll Cardiol 51 (2008) 2011-2016
15. Planer D., Beyar R., Almagor Y., et al. Long-term (>3 Years) outcome and predictors of clinical events after insertion of sirolimus-eluting stent in one or more native coronary arteries (from the Israeli arm of the e-Cypher registry). Am J Cardiol 101 (2008) 953-959
16. Flores-Ríos X., Marzoa-Rivas R., Abugattás-de Torres J.P., et al. Late thrombosis of paclitaxel-eluting stents: long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients. Am Heart J 155 (2008) 648-653
17. Daemen J., Tanimoto S., García-García H.M., et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 99 (2007) 1027-1032
18. de la Torre-Hernández J.M., Alfonso F., Hernández F., et al., ESTROFA Study Group. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 51 (2008) 986-990
19. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
20. Mauri L., Hsieh W.H., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
21. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
22. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
23. Farb A., Burke A.P., Kolodgie F.D., et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
24. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
25. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2133
26. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
27. Park D.W., Park S.W., Park K.H., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
28. Wiviott S.D., Braunwald E., McCabe C.H., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371 (2008) 1353-1363
29. Hong M.K., Mintz G.S., Lee C.W., et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 113 (2006) 414-419
30. Jiménez-Quevedo P., Sabaté M., Angiolillo D.J., et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 47 (2006) 2172-2179
31. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 49 (2007) 2312-2317
32. Galløe A.M., Thuesen L., Kelbaek H., et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 299 (2008) 409-416